Anebulo Pharmaceuticals, Inc.

NasdaqCM:ANEB Stock Report

Market Cap: US$44.1m

Anebulo Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Richie Cunningham

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage18.3%
CEO tenure1.2yrs
CEO ownershipn/a
Management average tenure1.9yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

CEO Compensation Analysis

How has Richie Cunningham's remuneration changed compared to Anebulo Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$8m

Jun 30 2024US$2mUS$333k

-US$8m

Compensation vs Market: Richie's total compensation ($USD1.82M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Insufficient data to compare Richie's compensation with company performance.

CEO

Richie Cunningham (53 yo)

1.2yrs

Tenure

US$1,819,383

Compensation

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Lawler
Founder & Chairman4.7yrsUS$83.11k46.27%
$ 20.4m
Richard Cunningham
CEO & Director1.2yrsUS$1.82mno data
Daniel George
Principal Accounting Officer1.3yrsUS$194.25kno data
Kenneth Cundy
Chief Scientific Officer2.6yrsUS$612.15k0%
$ 0

1.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: ANEB's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Joseph Lawler
Founder & Chairman4.7yrsUS$83.11k46.27%
$ 20.4m
Richard Cunningham
CEO & Director1.2yrsUS$1.82mno data
Bimal Shah
Independent Director1.2yrsUS$124.53k0%
$ 0
Kenneth Lin
Lead Independent Director3.8yrsUS$68.24k0%
$ 0
Areta Kupchyk
Independent Director3.7yrsUS$76.87k0%
$ 0
Jason Aryeh
Independent Director3.8yrsUS$83.24k0%
$ 0
Nathaniel Calloway
Independent Director2.2yrsUS$67.26k0%
$ 0
Aron English
Independent Director4.5yrsUS$66.87k17.95%
$ 7.9m
Andrew Monte
Member of Scientific Advisory Board3.9yrsno datano data
Arjun Chanmugam
Member of Scientific Advisory Board3.9yrsno datano data

3.8yrs

Average Tenure

52yo

Average Age

Experienced Board: ANEB's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 14:20
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anebulo Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company